Keyphrases
Recent-onset
100%
Psychotic Disorders
100%
Simvastatin
100%
Symptom Severity
60%
Placebo
40%
Cognitive Decline
40%
Brain Tissue Damage
40%
Randomized Controlled Trial
20%
Trial Registration
20%
Blood Samples
20%
Movement Disorders
20%
EudraCT
20%
Primary Outcome Measure
20%
Metabolic Syndrome
20%
Inflammatory Process
20%
Attenuation
20%
Pathophysiology of Schizophrenia
20%
Antipsychotics
20%
Treatment Response
20%
Inflammatory Activity
20%
Metabolic Parameters
20%
First-episode Psychosis
20%
Negative Syndrome
20%
Schizophrenia Spectrum Disorders
20%
End of Treatment
20%
Metabolic Syndrome Prevalence
20%
General Functioning
20%
Schizophrenia Symptoms
20%
Double-blind Placebo-controlled Trial
20%
Schizophrenia Treatment
20%
Anti-inflammatory Drugs
20%
Immunological Parameters
20%
Scale Assessment
20%
Vascular Protection
20%
Attractive Potential
20%
Brief Assessment of Cognition in Schizophrenia
20%
Related Disorders
20%
Method Design
20%
INIS
symptoms
100%
brain
100%
inflammation
100%
augmentation
100%
patients
66%
tissues
66%
drugs
66%
losses
66%
reduction
33%
comparative evaluations
33%
blood
33%
assessments
33%
spectra
33%
design
33%
protection
33%
attenuation
33%
psychoses
33%
Pharmacology, Toxicology and Pharmaceutical Science
Simvastatin
100%
Placebo
60%
Metabolic Syndrome X
40%
Randomized Controlled Trial
20%
Inflammation
20%
Prevalence
20%
Pathophysiology
20%
Motor Dysfunction
20%
Antipsychotic
20%
Antiinflammatory Agent
20%
Negative Syndrome
20%
Positive Syndrome
20%
Schizophrenia Spectrum Disorder
20%
Neuroscience
Simvastatin
100%
Placebo
60%
Randomized Controlled Trial
20%
Stereotypic Movement Disorder
20%
Anti-Inflammatory
20%
Negative Syndrome
20%
Positive Syndrome
20%
Schizophrenia Spectrum Disorder
20%
Treatment of Schizophrenia
20%
Antipsychotic
20%
Biochemistry, Genetics and Molecular Biology
Simvastatin
100%
Prevalence
20%
Randomized Controlled Trial
20%
Antipsychotic
20%